Novavax Files 8-K: Financials and Operations Update

Ticker: NVAX · Form: 8-K · Filed: May 10, 2024 · CIK: 1000694

Novavax Inc 8-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type8-K
Filed DateMay 10, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-results, operations-update

Related Tickers: NVAX

TL;DR

NOVAVAX filed an 8-K on May 10, 2024, updating investors on financials and operations.

AI Summary

On May 10, 2024, Novavax, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Specific financial figures and operational details are contained within the full report.

Why It Matters

This filing provides investors with crucial, up-to-date information on Novavax's financial health and operational status, which can influence investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial and operational news that may impact a company's stock price, requiring careful investor review.

Key Players & Entities

  • NOVAVAX, INC. (company) — Registrant
  • May 10, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 22-2816046 (tax_id) — I.R.S. Employer Identification No.
  • 700 Quince Orchard Road Gaithersburg, Maryland 20878 (address) — Principal Executive Offices
  • 240-268-2000 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing by Novavax, Inc.?

The primary purpose of this 8-K filing is to report on Novavax, Inc.'s Results of Operations and Financial Condition, along with providing Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on May 10, 2024.

What is Novavax, Inc.'s principal executive office address?

Novavax, Inc.'s principal executive office is located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.

In which U.S. state was Novavax, Inc. incorporated?

Novavax, Inc. was incorporated in Delaware.

What is the telephone number for Novavax, Inc.?

The telephone number for Novavax, Inc. is (240) 268-2000.

Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 9.1 · Accepted 2024-05-10 08:07:32

Key Financial Figures

  • $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Fourth Quarter Financial Results On May 10, 2024, Novavax, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended March 31, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated May 10, 2024, regarding the Company's financial results for the quarter ended March 31, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: May 10, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.